Christian Becker
Pulmonary Disease · New York, NYNPI 1629241369
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,250 of the $6,470 with a category attached, or 81.1%. Pharming Healthcare, Inc. accounts for 97.1% of it on its own, with 2 other manufacturers making up the rest.
Across 14 payments — averaging $462.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharming Healthcare, Inc.$6K
- Boston Scientific$170
- W. L. Gore & Associates, Inc.$18
Across 38 payments — averaging $3009.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mannkind Corporation$112K
- Boehringer Ingelheim International GmbH$3K
What the payments were for
- Consulting fees$5,25081%
- Travel & lodging$76812%
- Food & beverage$4527%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharming Healthcare, Inc. | 11 | $6,283 |
| Boston Scientific | 2 | $170 |
| W. L. Gore & Associates, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JOENJA$6,022
How this compares
$6,470 in reported general payments places this provider in the 75th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $43,032 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 54 | $25,419 |
| Incruse ElliptaUmeclidinium Bromide | 41 | $13,687 |
| Spiriva RespimatTiotropium Bromide | 17 | $13,612 |
| Advair HfaFluticasone Propion/Salmeterol | 25 | $9,847 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,646 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 192 | $6,471 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $3,788 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $3,755 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,570 |
| Ethambutol Hcl | 61 | $1,865 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $1,858 |
| Rifampin | 26 | $1,671 |
| Azithromycin | 70 | $941 |
| Roflumilast | 11 | $906 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in New York
- Charles PowellNew York$654K
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Monica KraftNew York$247K
- Jamie BessichNew York$226K
- Ronald CrystalNew York$213K
- Michael NiedermanNew York$176K
- Wilfredo TalaveraNew York$145K
- Josanna Rodriguez-LopezNew York$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.